Schwab, Silvia; Diem, Peter (2009). [Oral hypoglycaemic agents in 2009]. Therapeutische Umschau, 66(10), pp. 677-84. Bern: Huber
Full text not available from this repository. (Request a copy)Various new oral hypoglycaemic agents have been developed recently and have changed the therapy of type 2 diabetes mellitus. Six different classes of agents are available: Biguanides, sulfonylureas, glinides, glitazones, alpha-glucosidase inhibitors and dipeptidyl peptidase-4 inhibitors. The increasing number of these drugs does not facilitate the choice of the best medication for an individual patient. In the article we describe the specific mechanisms of action, side effects, advantages and disadvantages of the different agents. Every drug therapy should be supported by lifestyle changes. Despite all the new drugs type 2 diabetes is still a chronic and slowly progressive disease without chance of cure. Therefore, it is important to prevent type 2 diabetes by normalizing body weight and increasing physical exercise.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Endocrinology, Diabetology and Clinical Nutrition |
UniBE Contributor: |
Schwab, Silvia, Diem, Peter |
ISSN: |
0040-5930 |
Publisher: |
Huber |
Language: |
German |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 15:14 |
Last Modified: |
05 Dec 2022 14:22 |
PubMed ID: |
19830675 |
URI: |
https://boris.unibe.ch/id/eprint/32473 (FactScience: 197682) |
Actions (login required)
 |
Edit item |